JPRN-UMIN000003969已完成3 期
Adjuvant Chemotherapy Trial of S-1 for breast cancer with ER-positive and HER2-negative. - Adjuvant Chemotherapy Trial of S-1 for breast cancer with ER-positive and HER2-negative.
Department of Breast Surgery, Graduate School of Medicine, Kyoto University0 个研究点目标入组 1,930 人开始时间: 2011年4月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,930
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Active double cancer 2) Bilateral (synchronous or asynchronous) breast cancer, inflammatory breast cancer 3) A history of previous treatment with oral 5-fluorouracil derivatives for 2 weeks or longer (Patients who received intravenous 5-fluorouracil can be enrolled.) 4) Serious diarrhea 5) Serious complications 6) A history of myocardial infarction within the past 6 months, interstitial pneumonia, or allergy to fluoropyrimidine derivatives 7) Pregnant women, nursing women, or women who want to become pregnant 8) Patients judged to be unsuitable for enrollment in the study by their physicians
研究者
相似试验
已完成
不适用
"Adjuvant Chemotherapy Trial of S-1 for breast cancer with ER-positive and HER2-negative" Pharmacodynamics, Pharmacokinetics and Pharmacogenomics studyFemale patient with invasive breast cancerJPRN-UMIN000006194Graduate School of Medicine Kyoto University1,400
已完成
不适用
Phase I/II trial of adjuvant chemotherapy of S-1 with CDDP for Stage III gastric cancerStage III gastric cancerJPRN-UMIN000004734School of Medicine, Keio University18
尚未招募
不适用
Evaluation of neoadjuvant chemotherapy for breast cancer using contrast-enhanced ultrasound (CE-US) imagingbreast cancerJPRN-UMIN000022304Diagnosis Radiology of Tohoku University40
招募中
2 期
Phase II study of perioperative chemotherapy for cStage II and III thoracic esophageal canceresophageal cancerJPRN-jRCTs051200048Kitadani Junya27
已完成
不适用
Pilot study of neoadjuvant chemotherapy with S-1 and oxaliplatin clinical Stage III gastric cancerGastric cancerJPRN-UMIN000031388Kyoto Katsura Hospital20